Bone is not static tissue — it is continuously remodeled throughout life by the balanced activity of osteoblasts (bone-forming cells) and osteoclasts (bone-resorbing cells). Estrogen plays a critical role in maintaining this balance by suppressing osteoclast activity. When estrogen levels drop after menopause, osteoclast activity accelerates and bone resorption outpaces formation, producing the rapid phase of bone density loss that characterizes the first five to seven years after the final menstrual period.
Women can lose three to five percent of their bone mass per year during the early postmenopausal years — a rate that is ten times higher than in premenopausal women. By the time a woman is ten years past menopause, she may have lost twenty to thirty percent of her peak bone mass — a reduction that substantially increases her risk of osteoporotic fractures, including hip fractures that carry significant morbidity and mortality in older women.
The good news is that this process is neither inevitable nor unaddressable. Understanding when bone density screening is appropriate, what risk factors matter, and what interventions are available gives every postmenopausal woman the information she needs to protect her skeletal health for the long term.
While all postmenopausal women are at increased risk for bone density loss, certain factors significantly amplify that risk. Identifying your personal risk profile guides the urgency of screening and the aggressiveness of preventive or therapeutic management.
- Early menopause — natural menopause before age 45 or surgical menopause at any age means longer cumulative estrogen deficiency
- Low body weight or BMI — lower adipose tissue means less extraglandular estrogen production and less mechanical loading on bone
- Family history of osteoporosis or hip fracture — particularly a mother or sister with a hip fracture
- Long-term glucocorticoid (steroid) use — among the most significant medication-related risk factors for bone loss
- Smoking — directly toxic to osteoblasts and associated with lower estrogen levels
- Excessive alcohol consumption — three or more drinks per day is associated with accelerated bone loss
- Low lifetime calcium and vitamin D intake — inadequate building blocks for bone maintenance
- Sedentary lifestyle — weight-bearing exercise is one of the most important stimuli for bone formation
- Malabsorption conditions — including celiac disease and inflammatory bowel disease affecting calcium and vitamin D absorption
- Rheumatoid arthritis and other inflammatory conditions associated with accelerated bone loss
- Prior fracture from minimal trauma — a strong indicator of existing low bone density
Even women without multiple risk factors benefit from bone density screening at menopause and periodic monitoring thereafter. Bone density loss is asymptomatic until fracture occurs — making proactive screening the only way to identify and address it before significant loss has occurred.
Bone density screening provides the objective measurement needed to assess current bone health and guide management decisions. Understanding what the test measures and how to interpret the results is part of an informed discussion about bone health after menopause.
DEXA Scan — The Standard for Bone Density Measurement
Dual-energy X-ray absorptiometry (DEXA) is the standard method for measuring bone mineral density (BMD). It is a low-radiation imaging study that measures bone density at the lumbar spine and hip — the two sites most predictive of osteoporotic fracture risk. The scan takes approximately fifteen minutes, requires no special preparation, and produces a numerical measurement compared to reference standards. DEXA is recommended for all women age 65 and older and for postmenopausal women under 65 with any significant risk factors for osteoporosis.
T-scores — How Bone Density Results Are Interpreted
DEXA results are expressed as T-scores — a comparison of your bone density to the average peak bone density of young healthy adults. A T-score of 0 means bone density equal to the young adult average. A T-score of -1.0 means one standard deviation below the young adult average. Normal bone density is defined as a T-score of -1.0 or above. Osteopenia (low bone density) is a T-score between -1.0 and -2.5. Osteoporosis is a T-score of -2.5 or below. Each standard deviation decrease in T-score approximately doubles fracture risk, making even osteopenia a clinically significant finding warranting attention.
FRAX Score — Putting Bone Density in Fracture Risk Context
The FRAX (Fracture Risk Assessment Tool) calculates an individual’s ten-year probability of major osteoporotic fracture based on bone density results combined with clinical risk factors. It provides a more nuanced fracture risk estimate than bone density alone and is used to guide decisions about whether pharmacologic treatment is appropriate for women with osteopenia whose treatment need is not obvious from T-score alone. Dr. Andrei calculates FRAX scores as part of the bone health assessment and uses them to inform treatment recommendations.
Bone health management at Lapeer Women’s Health is led by Dr. Ramona D. Andrei, MD, PhD, FACOG — with an individualized approach that matches the intensity of intervention to the degree of bone loss and fracture risk.
Foundation — Calcium, Vitamin D, and Exercise
Adequate calcium (1,000 to 1,200 mg daily through diet and supplementation combined) and vitamin D (800 to 1,000 IU daily or more based on serum levels) are the nutritional foundations of bone health management. Regular weight-bearing exercise — walking, hiking, resistance training — provides the mechanical stimulus for bone formation that no medication replaces. These measures are recommended for all postmenopausal women regardless of bone density status.
Hormone Therapy — Prevention of Early Bone Loss
Hormone therapy is the most effective intervention for preventing the accelerated bone density loss of the early postmenopausal years. It works by restoring estrogen’s suppressive effect on osteoclast activity, slowing the resorption side of bone remodeling. For eligible candidates starting hormone therapy within the critical window, bone protection is one of the most important and durable long-term benefits of treatment. Women on hormone therapy maintain bone density at rates significantly better than untreated women during the early postmenopausal years.
Pharmacologic Treatment for Osteopenia and Osteoporosis
For women with osteoporosis or high-risk osteopenia for whom pharmacologic treatment is indicated, bisphosphonates (alendronate, risedronate, zoledronic acid) are the most widely used first-line agents. They reduce fracture risk by 30 to 50 percent in women with osteoporosis. Denosumab, raloxifene, and other agents are used in specific clinical contexts. Dr. Andrei discusses pharmacologic treatment options and initiates management when indicated — or coordinates with primary care when ongoing pharmacologic management is most appropriately managed there.
Osteoporosis is called a silent disease because it produces no symptoms until a fracture occurs. By the time a woman fractures a hip in her 70s, the bone density loss that made that fracture possible began twenty years earlier, in the first years after menopause. The window for most effective prevention is exactly the window most women are not thinking about bone health.
A bone density assessment at menopause — or at first presentation to Lapeer Women’s Health for any reason — establishes a baseline that guides prevention strategy and identifies the subset of women who need more aggressive intervention than diet and exercise alone. That knowledge is protective in a way that nothing else can replicate.
Dr. Ramona D. Andrei and the team at Lapeer Women’s Health are here to provide that assessment and a bone health plan — at both our Lapeer and Rochester Hills offices, without a referral required.
Bone Health After Menopause
Our team at Lapeer Women’s Health includes bone density assessment and individualized bone health planning as a core component of postmenopausal care — at both our Lapeer and Rochester Hills offices. No referral required.
Schedule a Gynecologic VisitThe information on this page is intended for educational purposes only and does not constitute medical advice. Content reviewed by Dr. Ramona D. Andrei, MD PhD FACOG.
Gynecologic care for women of every age
Lapeer Women’s Health — Rochester Hills
2710 S Rochester Rd, Suite 2
Rochester Hills, MI 48307
Serving patients in Lapeer, Rochester Hills, and surrounding communities throughout Southeast Michigan.